Establishment Labs Holdings Inc. research snapshot
ESTA AI stock analysis as of the August 4, 2026 data cutoff reads Establishment Labs Holdings Inc. as an accelerating medical aesthetics turnaround that the market is pricing optimistically. The stock closed at $92.80 on August 3, 2026, up 0.26 or 0.28% from the $92.54 close on July 31, after opening at $94.76 and touching a new 52-week high of $97.59 intraday before settling back, carrying a market capitalization near $2.73 billion on 29.43 million shares outstanding. The last reported quarter, Q1 2026, delivered revenue of $59.88 million, up 44.7% year over year, with US revenue of $19.59 million up about 216%, a gross margin of 70.7% up 350 basis points, and adjusted EBITDA of $1.2 million, the third consecutive quarter of positive adjusted EBITDA. Management raised full year 2026 revenue guidance to $266.5 million to $268.5 million and expects to reach cash flow positive in the second half of 2026. The stock is still not GAAP profitable, with TTM net income of about negative $43.74 million, and the valuation is demanding at roughly 11.9x TTM revenue and about 9.7x forward revenue. The next catalyst is the Q2 2026 earnings release scheduled for August 6, 2026, before market open. The main question is whether US Motiva adoption, the minimally invasive platform, and the pending FDA breast reconstruction submission can turn a premium revenue multiple into sustained GAAP earnings. This page is informational research and not investment advice.
Current price
$92.80 at the August 3, 2026, 4:00 PM EDT market close, up 0.26 or 0.28% from the $92.54 July 31 close, after opening at $94.76 and trading in a session range of $92.72 to $97.59, with the daily history table confirming the same $92.80 close on volume near 850,000 shares
Market cap
$2.73 billion reported by StockAnalysis.com at the August 3, 2026 market close, matching the $92.80 price times 29.43 million shares outstanding
AI score
64 / 100
Rating
Accelerating US turnaround at a premium valuation
Trend status
Uptrend above the 50-day and 200-day moving averages near $84.72 and $70.86, with a fresh 52-week high of $97.59 touched intraday on August 3, 2026
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Establishment Labs sells Motiva silicone breast implants, tissue expanders, and a minimally invasive platform into global aesthetic and reconstructive markets. Revenue is growing quickly, Q1 2026 was up 44.7%, and the US launch is the fastest part of the story, but the product remains elective and the company is not yet GAAP profitable. | Medium-high |
| Moat | The moat comes from surgeon training and certification, a proprietary four-micron surface technology backed by more than 200 patents issued and pending, low reported complication rates, brand awareness that 93% of surgeons who get a brand request say is Motiva, and a public post-market surveillance record. It is real but not unbreakable for well-funded competitors or an FDA delay. | Medium |
| Management | Management delivered a strong Q1 2026, raised 2026 guidance, refinanced debt with Oaktree, and reached three straight quarters of positive adjusted EBITDA. Flags include the founder selling about $7.9 million of shares on an earnings day and the CFO transition in May 2026, when Raj Denhoy left and Sandra Harris took over as CFO. | Medium |
| Financial trend | TTM revenue was about $229.58 million, up roughly 35% year over year. FY2025 revenue was $211.08 million, up 27.1%, and FY2026 guidance is $266.5 million to $268.5 million. The company still loses money on a GAAP basis, with TTM net income near negative $43.74 million and negative free cash flow of about $41.62 million, though adjusted EBITDA turned positive. | Medium-high |
| Valuation | The stock trades near 11.9x TTM revenue, about 9.7x forward revenue, and roughly 12.75x EV to TTM sales, with a negative PE. The valuation reflects future profitability expectations rather than current earnings, and it sits above the average analyst price target of $97.22. | Low |
| Technical trend | ESTA closed at $92.80 on August 3, 2026, above both the 50-day moving average near $84.72 and the 200-day moving average near $70.86, after touching a 52-week high of $97.59 intraday. RSI near 59.38 is positive but not overbought. | Medium-high |
| Risk level | Key risks are elective procedure sensitivity to consumer spending, competitive entry from larger medical device firms, the pace of US market adoption, FDA timing on breast reconstruction, net debt near $196 million, negative GAAP earnings, possible dilutive financing, and insider selling. | Medium-high |
| AI confidence | High confidence for filings, market data, Q1 2026 results, and technical levels that cross-validated during the August 4, 2026 refresh. Medium for future profitability timing, FDA approval, and whether the premium multiple holds. | Medium data confidence |
| Investment certainty | Low-medium certainty. ESTA has a strong and accelerating growth story, but the stock price already reflects optimistic assumptions about margin expansion and sustained growth, so the margin of safety is thin. | Low-medium |
ESTA AI stock forecast
The ESTA AI stock forecast uses scenario ranges around the $92.80 cutoff price. It does not claim that AI can predict a specific future price. The next major input is the Q2 2026 earnings release on August 6, 2026. The bullish case requires sustained US growth, minimally invasive scale, and a path to GAAP profitability. The base case assumes the company hits raised guidance but takes longer to convert premium revenue into durable earnings. The bearish case assumes US adoption stalls, competition intensifies, or the cash position forces dilutive financing.
$125 to $155
More likely if US revenue keeps growing at a high rate, the minimally invasive platform exceeds $35 million in 2026, the FDA breast reconstruction submission advances, the company reaches cash flow positive in the second half of 2026 and later reports GAAP profits, and investors keep a premium multiple on the improved margin profile.
$75 to $105
More likely if the company delivers the raised $266.5 million to $268.5 million guidance, US revenue stays above 30% of total, adjusted EBITDA stays positive, but GAAP profitability slips into 2027 and the multiple compresses toward 8x forward revenue.
$45 to $65
More likely if consumer spending on elective procedures weakens, a major competitor enters breast implants with disruptive pricing, the FDA reconstruction approval is delayed, growth decelerates while cash burn persists, or the balance sheet forces dilutive financing.
ESTA AI technical analysis
ESTA AI technical analysis starts from the $92.80 close on August 3, 2026, used for this static page. The stock is above its 50-day moving average near $84.72 and its 200-day moving average near $70.86, after touching a new 52-week high of $97.59 intraday on August 3, then closing below its opening price. Public technical sources show RSI near 59.38 and a beta of 1.09. Because this page does not fetch request-time market data, traders should confirm levels on a live chart before acting.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $92.80 | August 3, 2026 market close, up 0.26 or 0.28% from the $92.54 close on July 31, per StockAnalysis.com. |
| Near resistance | $95 to $98 | The $95.65 close on July 21 and the $97.59 intraday high on August 3 form the current resistance band. A clean close above this zone would open room toward $100. |
| 52-week high | $97.59 | Set intraday on August 3, 2026. The stock closed at $92.80 below its open that day, so the high needs volume confirmation. |
| Near support | $84 to $86 | The 50-day moving average area near $84.72 and the July 14 low near $83.85. This is the first level that matters if the stock pulls back. |
| Secondary support | $70 to $76 | The 200-day moving average near $70.86. A sustained break below this area would weaken the long-term technical setup. |
| 50-day moving average | About $84.72 | Public technical sources showed ESTA above its 50-day moving average around the August 4, 2026 cutoff. |
| 200-day moving average | About $70.86 | Public technical sources showed ESTA well above its 200-day moving average, supporting the long-term uptrend. |
| Momentum | RSI near 59.38 | Positive but not overbought. After the rally from about $33 to $93, momentum needs fresh volume to extend. |
| Volume | About 850,000 shares | August 3 volume ran above the 20-day average near 453,000, but a large part of the rally has traded below the June 26 volume spike near 5.3 million shares. |
| Volatility | Beta of 1.09, moderate volatility | Position sizing should account for normal daily swings in a small-cap medical device stock. |
| Invalidation | Close below $84, then $70 | A close below the 50-day area weakens the near-term setup. A break below the 200-day area would challenge the long trend. |
ESTA AI trading strategy
The ESTA AI trading strategy is a rules-based framework, not personalized advice. It combines filing-backed business evidence, technical confirmation, position sizing, and clear invalidation levels. The Q2 2026 earnings release on August 6, 2026 is an event risk that can move the stock sharply.
Look for ESTA to hold above the $84 to $86 support zone and close above the $95 to $98 resistance band with above-average volume before treating the breakout as confirmed.
A failed breakout or a daily close below the 50-day area should reduce confidence in the setup. Keep position size small into the August 6 earnings report.
If ESTA pulls back toward $84 to $86 without a thesis break, compare price stabilization with the August 6 earnings outcome, US adoption data, and margin progression signals.
Do not average down solely because the stock had a strong run. Define maximum loss and review valuation first.
Track Q2 2026 results on August 6, revenue growth, US revenue as a share of total, gross margin trend, minimally invasive revenue, adjusted EBITDA, free cash flow, the FDA reconstruction submission, silicone supply costs, and debt levels.
Lower the rating if revenue growth decelerates while the stock still trades at a premium revenue multiple, or if the balance sheet forces equity financing.
Investment research summary
Establishment Labs designs, manufactures, and sells Motiva-brand silicone breast implants, tissue expanders, and a minimally invasive platform (Mia and Preserve) for aesthetic and reconstructive surgery. Customers pay for safety data, surgeon training, and a premium brand in a market that has seen limited innovation since the 1992 US moratorium on silicone implants.
The moat is built on surgeon training and certification, a proprietary four-micron surface technology, more than 200 patents issued and pending, low reported complication rates including capsular contracture below 1%, brand awareness among surgeons, and a public post-market surveillance record that competitors do not share.
The thesis can fail if consumer spending on elective aesthetics weakens in an economic downturn, a larger competitor enters with price pressure, US market adoption stalls after the initial surge, the FDA delays breast reconstruction approval, silicone supply costs rise, or the company cannot reach GAAP profitability before the balance sheet forces dilutive capital.
Leadership delivered a strong Q1 2026, raised 2026 guidance to $266.5 million to $268.5 million, refinanced debt with Oaktree, and reached three straight quarters of positive adjusted EBITDA. Flags include the founder selling about $7.9 million of shares on an earnings day and the CFO transition in May 2026.
Establishment Labs operates at the intersection of medical aesthetics and a shift toward minimally invasive procedures. GLP-1 weight loss drugs are creating a new pool of potential patients, and the company says 15% of Preserve patients were new to the category, but elective aesthetics remain cyclical and consumer dependent.
At roughly 11.9x TTM revenue, about 9.7x forward revenue, and a negative PE, the price embeds optimistic assumptions about future profitability. A buyer needs confidence in sustained US growth, minimally invasive scale, and a credible path to GAAP profitability to justify the current multiple.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| ESTA price | $92.80 close on August 3, 2026, up 0.28% | StockAnalysis.com quote and daily history | August 4, 2026 |
| Market capitalization | $2.73 billion | StockAnalysis.com statistics | August 4, 2026 |
| Shares outstanding | 29.43 million | StockAnalysis.com statistics | August 4, 2026 |
| TTM revenue | $229.58 million, up about 34.9% | StockAnalysis.com financials | August 4, 2026 |
| TTM net income | About -$43.74 million | StockAnalysis.com financials | August 4, 2026 |
| Q1 FY2026 revenue | $59.88 million, up 44.7% | Establishment Labs Q1 2026 earnings release and call | August 4, 2026 |
| Q1 FY2026 US revenue | $19.59 million, up about 216%, 32.7% of total | Establishment Labs Q1 2026 earnings call | August 4, 2026 |
| FY2026 revenue guidance | $266.5 million to $268.5 million | Establishment Labs Q1 2026 earnings call | August 4, 2026 |
| Cash and equivalents | $68.10 million as of March 31, 2026 | StockAnalysis.com balance sheet | August 4, 2026 |
| Total debt | $251 million (10-Q basis) or $263.96 million (S&P Global statistics) | StockAnalysis.com balance sheet and statistics | August 4, 2026 |
| Enterprise value | $2.93 billion | StockAnalysis.com statistics | August 4, 2026 |
| Price to sales ratio (TTM) | About 11.90x | StockAnalysis.com statistics | August 4, 2026 |
| Analyst consensus | Strong Buy, 9 analysts, average target $97.22, high $117 | StockAnalysis.com forecast and ratings | August 4, 2026 |
| 52-week range | $33.35 to $97.59 | StockAnalysis.com quote and history | August 4, 2026 |
| Short interest | 4.48 million shares, 15.24% of shares outstanding | StockAnalysis.com statistics | August 4, 2026 |
| Next earnings date | August 6, 2026, before market open | StockAnalysis.com and Business Wire announcement | August 4, 2026 |
This ESTA AI stock analysis is an informational research tool only and is not investment advice, a recommendation, or a promise of future performance. Forecast scenarios are based on available public data as of August 4, 2026 and may be wrong if US adoption, minimally invasive growth, FDA timing, silicone supply costs, consumer spending on elective procedures, competitive dynamics, or valuation multiples change. GAAP financial figures for periods before Q1 2026 are presented as reported, and adjusted EBITDA is a non-GAAP measure from the company.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
